Commission announces reorganisation of portfolios:
This article was originally published in Clinica
European medical device legislation will in future be administered by the directorate general (DG) for enterprise following the reorganisation of the Commission, rather than by the new DG for health and consumer protection (see Clinica No 864, p 7). "This will not change our approach," said a Commission spokesman. The enterprise DG has been created by merging the DGs that represented industry and small and medium-sized enterprises. Its commissioner-designate is Erkki Liikanen, a former minister of finance in Finland. The European Parliament will vote on September 15 to formally approve the reorganisation.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.